A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Trial Profile

A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Silmitasertib (Primary) ; Cisplatin; Gemcitabine
  • Indications Cholangiocarcinoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Senhwa Biosciences
  • Most Recent Events

    • 19 Oct 2017 Planned number of patients changed from 100 to 209.
    • 19 Oct 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.
    • 19 Oct 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top